• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety and Tolerability of Systemic Beta-2-Adrenergic AgonistAlbuterol as Pharmacological Therapy in Non-Invasive Ventilation NIV -supported Amyotrophic Lateral SclerosisALSPatients with Chronic Respiratory Failure (P4.079)
CONCLUSIONS:Systemic albuterol is 94.2% tolerable when used in NIV-supported ALS patients.M NIV-supported ALS patients more commonly required albuterol.VC was maintained at 3 months without change but not at 6 months in albuterol-treated NIV-supported ALS patients.Further studies are required on pharmacologically enhancing the treatment of NIV-supported ALS patients.Study Supported by:Carolinas ALS Research Fund/Pinstripes Fund/Carolinas Garden of Hope/Carolinas Healthcare FoundationDisclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytoki...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Brooks, B., Kandinov, B., Langford, V., Lindblom, S., Sanjak, M., Wright, K., Ward, A., Holsten, S., Fischer, M., Lucas, N., Smith, N., Nichols, M., Lary, C., Nemeth, J., Russo, P., Bockenek, W., Bravver, E., Desai, U., Story, J. S., Pacicco, T. Tags: ALS: Trials and Biomarkers Source Type: research

Cerebral Vasoconstriction Triggered By Sympathomimetic Drugs During Intra-atrerial Chemotherapy
In this report, we highlight the potential risk of reversible cerebral vasoconstriction in children administered vasoactive drugs and discuss its relevance during treatment of retinoblastoma by intraarterial chemotherapy.
Source: Pediatric Neurology - January 21, 2013 Category: Neurology Authors: Todd Abruzzo, Mario Patino, James Leach, Ralph Rahme, James Geller Tags: Case Reports Source Type: research